New drug cocktail aims to shrink tough blood cancers
NCT ID NCT05371054
Summary
This early-phase study tested a new three-drug combination (VVIP) for adults with aggressive non-Hodgkin lymphomas that have returned or not responded to at least two prior treatments. The main goals were to find the safest dose and see if the treatment could make the cancer disappear completely. Eight participants received the drugs in repeating cycles, with treatment lasting up to two years and follow-up for five years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.